Eddingpharm (Cayman) Inc. closed a $24 million Series B financing
Eddingpharm (Cayman) Inc. closed a $24 million Series B financing. The round was co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Sequoia Capital China Growth Fund also participated in the financing. Eddingpharm is a specialty pharmaceutical marketing company focused on China. It plans to use the capital to in-licensing of drugs from suppliers, to co-develop prescription drugs and to seek potential M&A opportunities.
17 September 2010•5 mins read
